WilmerHale Advises Inozyme Pharma in $67 Million Series A2 Financing

  • 4.17.2019

On April 10, 2019, Inozyme Pharma, Inc., a biotechnology company developing novel medicines to treat rare, debilitating, and life-threatening mineralization disorders, announced that it raised $67 million in a Series A2 financing led by Pivotal bioVenture Partners and Sofinnova Investments. Cross-over investors, including RA Capital Management, Cowen Healthcare Investments, and Rock Springs Capital, as well as Inozyme’s previous investors, Longitude Capital, NEA, Novo Holdings, and Sanofi Ventures, also joined this round.

Brian Johnson led the WilmerHale team representing Inozyme in this transaction which included Peter Roth and Andrea Sorrentino.